Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

MIRACLE · Integrated multi-angle research and training network to eradicate leukemia minimal residual disease

HORIZONStatus: SIGNED1 December 202430 November 2028EU funding €2,637,950Call HORIZON-MSCA-2023-DN-01

An estimated 300,000 new cases of leukemia are diagnosed each year globally. The most common form of acute leukemia is acute myeloid leukemia (AML), which is generally a disease of the elderly, while acute lymphoid leukemia (ALL) is most prevalent in children. The biggest problem associated with leukemia treatment is persistence of residual therapy-resistant cancer cells, called minimal residual disease (MRD). MRD can latently persist in the patient for many months, and in response to unknown signals can reawaken and initiate a relapse, which is difficult to treat and responsible for the low survival rates of patients. Currently, knowledge on mechanisms responsible for persistence of MRD and initiation of leukemia relapse is lacking, making development of therapeutics eradicating MRD difficult and hampering improvement of patient cure rates. MIRACLE aims at eradication of MRD and development of clinically efficient treatment strategies that can deliver long-lasting benefit to patients by training a new generation of researchers.MIRACLE will elucidate the leukemia MRD landscape by integrating the knowledge on mechanisms driving persistence of MRD from different angles, and by the subsequent design of efficient and less toxic, novel targeted combination therapy with increased capacity to induce deep responses in patients. With its multidisciplinary team of scientists from academia and industry MIRACLE aims to educate a new generation of researchers optimally equipped to advance and accelerate development of novel therapeutics directed to MRD, and to progress effective treatments to the clinic. The researchers within MIRACLE will be trained to obtain a unique combination of skills in innovative high-tech technologies, advanced data analysis tools and artificial intelligence, organ-on-chip MRD models, and drug and immunotherapy testing, and will come with innovative ideas to advance future leukemia treatment by integration of several disciplines and data sources.

Consortium · 22 organisations

coordinator

STICHTING AMSTERDAM UMC

NL · €548,741

participant

MIMETAS BV

NL · €274,370

associatedPartner

Stichting Hematon

NL

participant

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

DE · €260,539

associatedPartner

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

UK

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €282,694

associatedPartner

STICHTING VU

NL

associatedPartner

ORTEC OPTIMIZATION TECHNOLOGY BV

NL

associatedPartner

Fundament Subsidieadvies

NL

associatedPartner

KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET

DE

associatedPartner

SOMERSAULT18:24

BE

participant

OSPEDALE SAN RAFFAELE SRL

IT · €259,438

participant

JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN

DE · €260,539

associatedPartner

STICHTING PROEFDIERVRIJ* DUTCH SOCIETY FOR THE REPLACEMENT OF ANIMAL TESTING

NL

participant

VIB VZW

BE · €262,620

associatedPartner

Brain & Body Company

NL

participant

UNIVERZITA KARLOVA

CZ · €237,038

associatedPartner

Active Motif

BE

associatedPartner

Institute of Biomedical Research of Salamanca (IBSAL)

ES

associatedPartner

KATHOLIEKE UNIVERSITEIT LEUVEN

BE

associatedPartner

UNIVERSITA VITA-SALUTE SAN RAFFAELE

IT

participant

UNIVERSIDAD DE SEVILLA

ES · €251,971

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.